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ABSTRACT
Understanding the factors that regulate hematopoiesis
opens up the possibility of modifying these factors and
their actions for clinical benefit. DEK, a non-histone
nuclear phosphoprotein initially identified as a putative
proto-oncogene, has recently been linked to regulate hem-
atopoiesis. DEK has myelosuppressive activity in vitro on
proliferation of human and mouse hematopoietic progeni-
tor cells and enhancing activity on engraftment of long-
term marrow repopulating mouse stem cells, has been
linked in coordinate regulation with the transcription fac-
tor C/EBPa, for differentiation of myeloid cells, and appa-
rently targets a long-term repopulating hematopoietic
stem cell for leukemic transformation. This review covers
the uniqueness of DEK, what is known about how it now
functions as a nuclear protein and also as a secreted mole-
cule that can act in paracrine fashion, and how it may be
regulated in part by dipeptidylpeptidase 4, an enzyme
known to truncate and modify a number of proteins
involved in activities on hematopoietic cells. Examples are
provided of possible future areas of investigation needed
to better understand how DEK may be regulated and
function as a regulator of hematopoiesis, information pos-
sibly translatable to other normal and diseased immature
cell systems. STEM CELLS 2013;31:1447–1453
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INTRODUCTION
Hematopoietic stem cell (HSCs) and hematopoietic progenitor
cells (HPCs) give rise to all blood forming elements and have
been used to successfully treat non-malignant and malignant
disorders [1, 2]. However, much remains to be deciphered
regarding regulation of HSC and HPC function and fate. In
efforts to uncover key factors involved in HSC and HPC pro-
duction and fate decisions, we identified DEK, a biochemi-
cally distinct mammalian nuclear phosphoprotein initially
classified as a putative proto-oncoprotein [3], as a candidate
for regulating hematopoiesis [4]. We noted that DEK had
negative regulatory effects on proliferation of HPCs: granulo-
cyte–macrophage (CFU-GM), erythroid (BFU-E), and multi-
potential (CFU-GEMM), but positive effects on engrafting
HSCs [4]. Others have linked DEK in coordinate regulation
with the transcription factor C/EBPa on the differentiation of
myeloid cells [5]. This complex of C/EBPa and DEK, whose
assembly and disassembly is regulated by serine 21 phospho-
rylation of C/EBPa, enhanced the activation of the
granulocyte-colony stimulating factor receptor 3 promotor.
Knocking down expression of the DEK gene reduced the
capacity of C/EBPa to drive granulocyte target gene expres-
sion. We recently reported that the cell surface enzyme
CD26, a dipeptidylpeptidase 4 (DPP4), truncates and changes
the functional activities of cytokines such as the colony stim-
ulating factors (CSFs: GM-CSF, granulocyte-CSF [G-CSF],
interleukin-3 [IL-3], and erythropoietin [EPO]) and of the
chemokine, stromal derived factor-1 (SDF-1/CXCL12) [6, 7].
We now know that other proteins with cell regulatory activity
have putative truncation sites for DPP4 [8, 9]. As discussed
below, DEK has a putative specific truncation site for DPP4.
Based on this information, we hypothesize that DEK is a key
and perhaps crucial regulatory determinant of HSC and HPC
function and fate decisions in both steady-state and stressed
hematopoiesis, effects that may be mediated or regulated by
DPP4 truncation of DEK.
There is still a paucity of information on DEK and its
actions. This review covers current knowledge of DEK and
its role in cell regulation and fate decisions, with a particular
emphasis on HSC, HPC, and hematopoiesis. Examples are
suggested for future studies in this area.
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DEK REGULATION AND ACTIVITIES
DEK bears little resemblance to other known proteins (Fig.
1A), and is the only representative of its own protein class.
While DEK, an abundant non-histone chromosomal factor, is
vital to global heterochromatin integrity [10] (Fig. 1B, 1C), it
can be secreted by certain cells, sometimes in exosomes, or in
its free form and subsequently be taken up as the same mole-
cule in bioactive form in a heparin sulfate-dependent process
by other cells where it, in turn, modulates global chromatin
structure [11], a process similar to what is seen in a paracrine
loop. Whether uptake of DEK can also take place through G-
Protein-coupled receptors or whether DEK can act through
stimulation of such receptors is not clear, and this may vary
between cell types and their maturational status.
DEK is heavily post-translationally modified. Regulation
of the phosphorylation status of DEK by CK2 and protein
phosphatase 2A [12, 13], acetylation [14, 15], and poly
(ADP-ribosyl)ation [16, 17] can regulate the function of
DEK. Transcription of the DEK gene is controlled by YY1
and NF-Y [18], E2F [19], and the estrogen receptor a [20].
The DEK protein can be degraded by the F-box/WD repeat
containing protein 7 (Fbxwt) [21], and microRNA-489, which
is involved in the maintenance of muscle stem-cell quies-
cence, does so by targeting DEK [22]. DEK interacts with
RelA/p65 [23] and represses gene expression in conjunction
with SET and PARP1 [24]. Phosphorylation by protein kinase
CK2 [12] in one way affects the function of the DNA-binding
domains (SAP-box and C-terminal DNA binding domain) of
DEK [25] and in another way allows for the histone chaper-
one functions of DEK that co-activate transcription of a
nuclear receptor [26]. However, CK2 does not seem to play a
role in regulating DEK’s function in chromatin integrity [12].
Blood cell production is regulated by cytokine and micro-
environmental influences that direct HSC and HPC functions
and fate decisions [2, 27]. Knowledge of these influences and
how they are mechanistically mediated is crucial to under-
standing hematopoiesis under steady-state and stress condi-
tions, and eventually for correction of the abnormalities in
hematopoiesis associated with disease, and for optimal effi-
cacy in the use of HSC and HPC for hematopoietic cell trans-
plantation. Our knowledge of the extracellular and
intracellular factors influencing the proliferation, self-renewal,
survival, differentiation, and movement of HSC and HPC is
increasing [2, 27], but there is still much to be learned if we
are to best use this information for improved health care. In
continuing efforts to define new factors in the regulation of
hematopoiesis, we focused on DEK, a non-histone phospho-
protein which was initially identified as a fusion protein
resulting from a t(6;9) translocation in a rare subtype of acute
myelogenous leukemia [3]. Furthermore, DEK is overex-
pressed and implicated in many malignancies [3, 28–38] and
exhibits critical functions in several central tumor-promoting
pathways, for example, inhibition of apoptosis and senes-
cence, among others [3, 28, 30, 33, 37, 39, 40]. DEK bears
little resemblance to other known proteins, but is well-
conserved among higher eukaryotes, as all DEK proteins
share a unique conserved region, the “SAP-box” (SAP5 Saf/
Actinus/PARP) [41]. This motif is found in proteins such as
DEK that are typically involved in DNA binding, chromatin
remodeling, and/or RNA processing [41–43]. DEK is capable
of binding to the TG-rich pets site in the human immunodefi-
ciency virus type 2 (HIV-2) promoter, where it acts as a tran-
scriptional repressor [13, 44], although it appears that DEK
primarily recognizes DNA on the basis of structure rather
than sequence and thus might play an active role in maintain-
ing higher-order chromatin architecture [42, 43, 45, 46]. In
addition to its DNA binding properties, DEK is found in asso-
ciation with messenger RNA splicing and export factors, as
well as with spliced transcripts, where it influences 30 splice
fidelity [46–50]. Intense post-translational modification of
DEK by phosphorylation [12], acetylation [14–16], and poly(-
ADP-ribosyl)ation [17] point to the importance of these post-
translational modifications in regulating DEK’s multiple func-
tions and subcellular or extracellular localization. DEK anti-
bodies are found in patients with juvenile idiopathic arthritis
and other auto-immune diseases [15, 51, 52], raising the ques-
tion of why this nuclear protein is an autoantigen. Although
DEK is primarily associated with chromatin throughout the
cell cycle [53], two independent pathways, both involving
post-translational modifications, were recently identified that
result in DEK’s presence in the extracellular space. The first
pathway implicated nonclassical secretion of DEK by acti-
vated human monocyte-derived macrophages in both a free
form and in exosomes [54]. In the second, passive release of
Figure 1. Schematic depiction of the structure, functional domains,
and post-translational modifications of DEK, potential DEK uptake
pathways, and effects of DEK on hematopoiesis. (A): Linear
sequence of DEK with DNA binding domains (yellow: pseudo-SAP-
box; green: SAP-box; blue: C-terminal DNA-binding domain; orange
lines: position of a-helices, as revealed by nuclear magnetic reso-
nance), and other functional features (red: acidic regions; black: puta-
tive NLS) indicated [See refs. 25, 41, 42, 44, 45]. The positions of
previously mapped phosphorylation and acetylation sites are marked
[See refs. 12, 14, 15]. (B): Potential DEK receptor mediated and/or
uptake pathways. (C): Simplified depiction of DEK functions in the
setting of chromatin. DEK interacts with, and augments binding of
HP1 to H3K9Me3, thereby recruiting SUV39H1/2, thus further
enhancing the deposition of H3K9Me3. In addition, DEK binds to
DNA/chromatin via its DNA binding domains (see A). However, the
precise consequences for open or closed chromatin currently remain
elusive. (D): Functional consequences of DEK in the setting of hema-
topoietic stem and progenitor cells. Not shown is the potential influ-
ence of dipeptidylpeptidase 4 truncation of DEK on DEK functional
activity. Abbreviations: HPC, hematopoietic progenitor cells; HSC,
hematopoietic stem cells.
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poly(ADP-ribosyl)ated, hyperphosphorylated DEK by apopto-
tic T-lymphocytes was observed possibly occurring as a result
of Fas-ligand- or stress-mediated apoptosis [16]. IL-8 induces
the secretion of DEK, and DEK acts as a chemoattractant for
peripheral blood leukocytes [54]. Of particular note in this
context, secreted DEK can be taken up by other cells, move
to the nucleus, and effectively carry out the intranuclear func-
tions of DEK, including control of global heterochromatin
integrity and DNA repair [11].
DEK AND HEMATOPOIESIS
Extracellular and intracellular DEK expression modulates
hematopoiesis [4]. It remains to be determined exactly how
DEK is mediating its different effects on hematopoiesis. This
may be through receptor mediated cytokine-like activities in
which a sequence of intracellular signals are induced, or per-
haps by cellular uptake through a specific receptor, and/or
non-receptor mediated DEK uptake. Uptake of DEK through
receptor-mediated or non-receptor-mediated events may
involve chromatin regulation (Fig. 1B, 1C). These different
possibilities require additional investigation. Exploring these
possibilities is important for understanding the effects of DEK
and perhaps for casting new light on regulation of hematopoi-
esis during health and disease.
We found that DEK, in purified recombinant human form,
was myelosuppressive for colony formation by CFU-GM,
BFU-E, and CFU-GEMM from C57Bl/6 mouse bone marrow
(BM) and human CB cells, effects that were dose-dependent
[4]. The suppressive effects of DEK on colony formation
were apparent when assayed on single isolated CD341 cord
blood (CB) cells, suggesting direct acting effects of DEK on
HPC although how these effects are mediated is not known.
This negative regulatory role of DEK was consistent with the
enhanced numbers and cycling status of CFU-GM, BFU-E,
and CFU-GEMM in the BM and spleen of C57Bl/6 DEK2/2,
compared with C57Bl/61/1, mice [4]. Some of this effect
may reflect the reports of others showing that DEK works in
concert with C/EBPa to regulate differentiation of myeloid
cells [5]. Most recently, we found similar effects using cells
from DEK2/2 mice on another mouse strain background.
DBA/1 DEK2/2 HPCs were at a higher cell cycling rate than
DBA/1 DEK1/1 HPCs (Fig. 2). Moreover, purified
recombinant human DEK-inhibited colony formation of DBA/
11/1 CFU-GM, BFU-E, and CFU-GEMM in dose-response
fashion (Broxmeyer unpublished observations). These results
demonstrate that the findings are not confined to effects on
only one mouse strain. In contrast to the inhibition of CFU
proliferation by DEK, BM cells from C57Bl/6 DEK2/2 mice
manifested decreased longer-, but not short-, term competitive
repopulation capability in lethally irradiated congenic mice, in
addition to even greater decreases in repopulation of lethally
irradiated secondary mouse recipients in a noncompetitive
assay [4]. This suggested that DEK was important for the pos-
itive engrafting capability of a long-term, but not short-term,
repopulating and self-renewing HSC (schematically shown in
Fig. 1D). The results suggest that DEK may be necessary for
maintenance of HSC, consistent with reports that DEK is
expressed in immature cell populations and that this expres-
sion decreases with the differentiation and maturing of the
cells [55]. Interestingly, the DEK/CAN fusion protein result-
ing from the t(6;9) chromosomal translocation [3] targets a
long-term repopulating HSC for leukemic transformation [56].
Still to be determined are effects of exogenously added
DEK on HSC and HPC numbers and functional activity, and
hematopoiesis in vivo, and possible effects of DEK on ex
vivo expansion of HSC and HPC, information that could pos-
sibly be of therapeutic use. The functional DEK domains that
may be involved in DEK receptor-binding and/or non-
receptor mediated uptake and translocation to the nucleus
remain to be determined, although DEK does have a putative
nuclear localization domain (Fig. 1).
DEK AND DPP4
We recently found that in addition to the homing and chemo-
tactic protein SDF-1/CXCL12 [7, 57], GM-CSF, G-CSF, IL-
3, and EPO have truncation sites for the enzyme DPP4 [6].
DPP4 is found on the surface of many cells as CD26 and is
present within cells expressing CD26. It is also found as a
soluble enzyme in serum and plasma. DPP4 treatment of
SDF-1/CXCL12 produces a molecule in which the two N-
terminal amino acids have been removed. Truncated SDF-1/
CXCL12 is inactive as an HPC chemotactic molecule and as
an HPC survival enhancing factor, and this truncated SDF-1/
CXCL12 can block the chemotactic and survival enhancing
Figure 2. Effects of DEK knockout (2/2) on hematopoietic progenitor cells. Results are shown for these cells in S-phase of the cell cycle, as deter-
mined by high specific activity tritiated thymidine kill technique, when stimulated with 5% pokeweed mitogen spleen cell conditioned medium
(PWMSCM), SCF (50 ng/ml), and erythropoietin (1 U/ml) in methylcellulose culture (A) and when stimulated with GM-CSF (10 ng/ml) alone and in
combination with SCF in agar culture (B) [6]. Results are given as mean6 SEM of three mice per group. *, significantly different from control
medium (p < .05), as assessed by two tailed t-test. Abbreviations: BFU-E, burst forming unit-erythroid; CFU, colony forming unit; CSF, colony stim-
ulating factor; GEMM, granulocyte–macrophage multipotential; GM, granulocyte–macrophage; SCF, stem cell factor; WT, wild type.
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effect of the full-length SDF-1/CXCL12 molecule [6, 7].
DPP4 treatment of GM-CSF, G-CSF, IL-3, and EPO produced
truncated forms of these CSFs that had greatly decreased CSF
activity, but blocked the activity of the full-length forms of
their respective CSF, for colony formation in vitro, and with
human GM-CSF for intracellular signaling (phosphorylation)
of JAK2 and STAT5 using TF1, a human factor dependent
cell line, and primary CD341 CB cells [6]. These in vitro
effects on HPC proliferation were duplicated in vivo in mice
given exogenously added full-length, truncated, or the combi-
nation of full-length and truncated GM-CSF, and also for full-
length and truncated EPO [6]. The effects were most apparent
on target cells pretreated with an inhibitor of DPP4 (e.g.,
Diprotin A; a tripeptide: ILE-PRO-ILE) or in CD262/2 mice.
Both radiolabeled full-length and truncated human GM-CSF
demonstrated receptor binding to the GM-CSF receptor of
TF1 cells and primary CD341 CB cells, but the truncated
GM-CSF bound to the GM-CSF receptor with higher affinity
(had a lower dissociation constant), and truncated GM-CSF
blocked receptor binding of full-length GM-CSF at concentra-
tions of truncated GM-CSF one-eighth that of full-length
GM-CSF [6]. Thus, DPP4-treated and truncated SDF-1/
CXCL12, GM-CSF, G-CSF, IL-3, and EPO act as dominant
negative or competitive molecules for the actions of their
respective full-length proteins, and offer a potential means for
regulating specific protein actions, and it may be that DEK
works in a similar fashion.
DPP4 can truncate proteins at a penultimate alanine or
proline at the N-terminus and also when serine or other amino
acids are at this penultimate site [8, 9]. Most recently, we
found that the N-terminus start site of the DEK protein con-
tained a putative DPP4 truncation site (MSASAPAAE-
GEGTPTQP …) in which serine (the second amino acid in
this sequence), rather than alanine or proline, served as a
potential site for DPP4 activity, unless in this case methionine
is preclipped off and it is the alanine (the second amino acid
in the following N-terminus sequence) that serves as a DPP4
truncation site (SASAPAAEGEGTPTQP …). As shown in
Figure 3, DPP4-treated DEK did not manifest inhibitory activ-
ity against GM-CSF- or GM-CSF plus SCF stimulated colony
formation of mouse BM cells pretreated with Diprotin A, an
inhibitor of DPP4, and at one-fourth to one-eighth the concen-
tration of untreated DEK, the DPP4-treated DEK blocked the
inhibitory activity of full-length DEK, suggesting that DPP4-
treated DEK can act as a dominant negative effector molecule
for full-length DEK, perhaps at the level of specific DEK
receptor binding or non-receptor mediated uptake. Whether
DPP4 truncates at the second amino acid (serine) or if the
methionine is preclipped and DPP4 truncates at the alanine
that follows the serine, this would leave the next sets of
amino acids open, with potential additional truncation sites
(serine, alanine, or proline) available, so that DPP4 may be
able to continue to truncate DEK. It remains to be determined
by mass spectrometry or other analysis what the effects of
DPP4 are on the DEK protein itself and where exactly the
DPP4 may be acting. Such analysis needs to be linked to
functional effects of DEK. These results, which need to be
pursued in greater depth both in vitro and in vivo, suggest a
potentially strong and modifying influence of DPP4 on DEK
activity, which may be of physiological relevance, and of
potential clinical interest.
Future efforts to more precisely define hematopoiesis in
DEK2/2 mice seem reasonable in the context of steady-state
hematopoiesis, and especially for hematopoiesis in mice sub-
jected to different stresses. We recently evaluated the effects
of radiation and drugs in CD262/2 mice [6]. Stress situations
can help define the relevance of DEK in a way that may not
be picked up using untreated mice. The stresses to be eval-
uated for hematological recovery can be low and higher non-
lethal c-irradiation, and non-lethal doses of drugs such as 5
fluorouracil and cyclophosphamide (Cytoxan).
In depth studies on mechanisms of DEK activities might
best be carried out on relevant established cell lines with con-
firming studies on primary target cells, such as we recently
published for GM-CSF [6]. We have identified the human
factor-dependent cell lines, TF1 (responsive to stimulation of
proliferation by GM-CSF, IL-3, or EPO, and when used in
combination with SCF eliciting a synergistic stimulating
effect) and M07e (responsive to GM-CSF or IL-3, and syn-
ergistically to either GM-CSF or IL-3 with SCF) as respond-
ing to the inhibitory effects of DEK with a 1 hour pulse
exposure of these cell lines to DEK (Fig. 4). TF1 [6] and
Figure 3. Influence of dipeptidylpeptidase 4 (DPP4) on DEK activity. Shown are effects of full-length (FL) – and DPP4-treated (5 likely trun-
cated, TR) DEK, alone and in combination, on 5 3 104 C57Bl/6 mouse BM cells/ml pretreated with diprotin A, an inhibitor of DPP4, and stimu-
lated with GM-CSF (Exp#1) or GM-CSF1SCF (Exp#2) (See ref. 6] for details of such studies carried out with other growth modulating
proteins). Results are given as mean6 SEM. *, significantly different from control medium (p < .05). Abbreviations: FL, full-length; ND, not
done; TR, truncated.
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M07e cells express active DPP4 on their cell surface as
CD26, (H. O’Leary and H.E. Broxmeyer, unpublished stud-
ies), as do HPC and HSC in primary mouse and human BM
and human CB [6, 7]. Although the effects of cytokines with
DPP4 truncation sites are more potent on CD26-expressing
cells that have been pretreated to inhibit DPP4 [6] (H.E.
Broxmeyer, unpublished observations), the activities of these
cytokines can still be detected although at a lesser effect if
the CD26-expressing cells are not pretreated to inhibit DPP4.
Much work remains to elucidate a role for DPP4 on protein
activity [8, 9]. Hence, although the TF1 and M07e cells were
not first pretreated to inhibit DPP4, we did detect DEK inhibi-
tion of colony formation by these cell lines. As both cell lines
have been used by us as models for stimulating and nega-
tively acting cytokines at a cell and intracellular level [58–
68], these growth factor dependent human cell lines can be
used as models to initiate intracellular studies on DEK signal
transduction, effects which can then be verified in less exten-
sive studies using, for example, primary CD341 CB cells, as
we reported previously for GM-CSF [6].
As communication between BM microenvironmental cells
and the HSC and HPC that reside in the BM is involved in
HSC and HPC function and fate decisions, and DEK is
expressed in osteoblasts, endothelial cells, and BM stromal
cells (authors of the studies in ref. 69–71 deposited their gene
expression data sets into the GEO profiles), DEK may be
involved in microenvironmental cell-HSC/HPC interactions,
perhaps with regards to positive effects we have noted with
DEK on engrafting capability of HSC and DEK negative regu-
lation of HPC. Such possible influences can be investigated in
a stem cell transplant model that can distinguish donor (e.g.,
CD45.21) from recipient (e.g., CD45.11/CD45.21 F1) from
competitor (e.g., CD45.11) cells in a competitive HSC setting,
and also donor from recipient cells in a non-competitive HSC
transplant assay. DEK2/2 mice (on a C57Bl/6 mouse strain
background) can be used alternatively as recipients and/or as a
source of donor cells.
CONCLUDING COMMENTS
In summary, DEK is an apparently unique molecule whose
functional activity in the normal regulation of HSC and HPC
cells [4, 5], and in leukemogenesis [56], is only just begin-
ning to be elucidated. It is likely that DEK will be found to
have controlling roles in other stem and progenitor cell types
in addition to those in muscle [22], including embryonic stem
cells, induced pluripotent stem cells, and mesenchymal stem/
stromal cells. Abnormalities in DEK and its actions may be
associated with cancer and cancer stem/progenitor cells [28,
72]. How DEK fits in with other chromatin and intracellular
molecules involved in regulation of HSC and HPC [2, 27] is
of great interest, and remains to be determined. DEK modu-
lates global heterochromatin integrity in human cells and in a
Drosophila model [10]. Interference with DEK expression in
human cells induces a phenotype indicative of more accessi-
ble chromatin organization. DEK is a Su(var), meaning that it
is a positive modulator of heterochromatin as shown using the
model of white-mottled variegation in the eyes of Drosophila
[10] (Fig. 1C). Loss of DEK is accompanied by loss of the
key heterochromatic marker H3K9Me3, and both phosphoryl-
ated and unphosphorylated DEK interact with the vital hetero-
chromatin factor HP1a, thus bringing HP1a to the H3K9
mark. DEK also plays a key role in epigenetic silencing by
bringing the KMT1 A/B methylase (which adds the third
methyl group to H3K9), along with HP1a, to what becomes
the H3K9Me3 mark, a hallmark of heterochromatin [10]. This
was shown by CHIP analysis, co-immunoprecipitation, and
biochemical interactions. Thus, it is of interest to determine if
uptake of DEK into HSCs and HPCs leads to changes in chro-
matin architecture with the subsequent effects on gene expres-
sion leading to effects on hematopoiesis. To further
understand the mechanism of action of DEK in hematopoiesis,
it will be essential to determine whether DEK effects are
mediated via specific receptors with subsequent induction of
intracellular signaling and/or by uptake and translocation of
DEK into the cytoplasm and subsequently into the nucleus
(Fig. 1B, 1C). It will be important to identify the domains of
DEK that are responsible for the effects on HSC and HPC,
and whether they are the same domains that are involved in
DNA binding and heterochromatin integrity [23]. A search for
a specific receptor or receptors for DEK is currently ongoing.
In the context of tumor cell sensitivity to chemotherapy, up-
regulation of DEK expression may enhance cell survival and
chemoresistance, while decreasing DEK expression in such
cells may enhance the sensitivity of the tumor cells to kill by
specific chemotherapeutic agents [33, 34, 39, 73]. As DEK
expression is higher in immature compared with more mature
blood cells such as those present in the CD341cell population
[55], and leukemia (LIC) or tumor (TIC) initiating cells pres-
ent in the CD341 cell population [2, 27], DEK could be one
of the reasons that LIC or TIC populations survive chemother-
apy. Also of interest is the effect of DPP4 truncation of DEK
on these functional activities of DEK. Therefore, further
understanding the function and molecular mechanisms of
action of this biochemically distinct protein, including assess-
ment of protein partners, DNA and RNA targets and the secre-
tion and uptake by neighboring cells, is likely to yield
information relevant to clinically important questions.
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